Results 11 to 20 of about 155 (115)

Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report

Pharmaceuticals
Background/Objectives: Ketamine/esketamine has a rapid/robust antidepressant effect on treatment-resistant depression (TRD). However, its long-term cognitive effects remain unclear.
Matildes de Freitas Menezes Sobreiro, Paulo Sergio Panse Silveira, Vitor Breseghello Cavenaghi, Leandro Paulino da Costa, Bruno Pinatti Ferreira de Souza, Rachel Emy Straus Takahashi, Renato Vianna Marotta Starek, José Oliveira Siqueira, Renerio Fraguas   +8 more
doaj   +3 more sources

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics

Neuropsychiatric Disease and Treatment, 2023
Lien Wang,1,2 Xiaowei Chen,1 Xiaojing Gu,1 Heidi De Smedt,3 Vanina Popova,3 Dong-Jing Fu,4 Carla M Canuso,4 Wayne C Drevets,2 Guang Chen2 1Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Shanghai, People’s ...
Wang L, Chen X, Gu X, De Smedt H, Popova V, Fu DJ, Canuso CM, Drevets WC, Chen G   +8 more
doaj   +3 more sources

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study

Frontiers in Psychiatry
IntroductionTreatment resistant depression (TRD) affects approximately 10–30% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT).
Albino J. Oliveira-Maia, Albino J. Oliveira-Maia, Benoît Rive, Yordan Godinov, Siobhán Mulhern-Haughey   +4 more
doaj   +3 more sources

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Neurology and Therapy
Introduction While the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited.
Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Aditi Shah, Hannah E. Bowrey, Anabelle Tardif-Samson, Dominic Pilon, Kruti Joshi   +8 more
doaj   +3 more sources

Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression

Biomarkers in Neuropsychiatry
Treatment-resistant depression, defined as a failure of at least two oral antidepressants of adequate dose and duration in the current episode, is a debilitating condition with low rates of response and remission.
Maxwell Z. Price, Richard L. Price
doaj   +2 more sources

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

European Psychiatry
Background Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits.
Andreas Reif, Bernhard T. Baune, Jozefien Buyze, Anthony J. Cleare, Shaun Johnson, Yerkebulan Kambarov, Nigel Olisa, Falk Schuster, Christian von Holt, Tamara Werner-Kiechle, Eduard Vieta   +10 more
doaj   +4 more sources

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression

Journal of Comparative Effectiveness Research
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials &
Kristin Clemens, Amanda Teeple, Benoit Rive, Noam Kirson, Urvi Desai, Jason Doran, Diab Eid, Alice Qu, Hannah Bowrey, Kruti Joshi   +9 more
doaj   +3 more sources

Esketamine Nasal Spray for Treatment-Resistant Depression [PDF]

Nursing for Women's Health, 2020
Major depression affects millions of adults in the United States, and women are affected at twice the rate of men. Approximately 30% of individuals may continue to experience depression symptoms despite treatment with oral antidepressants. In March 2019, the U.S.
openaire   +3 more sources

Esketamine Nasal Spray versus Quetiapine for Resistant Depression

New England Journal of Medicine
Horowitz, Mark A, Plöderl, Martin, Naudet, Florian   +2 more
exaly   +5 more sources

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

BMC Psychiatry, 2021
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD).
Nagahide Takahashi, Aya Yamada, Ayako Shiraishi, Hiroko Shimizu, Ryosuke Goto, Yushin Tominaga   +5 more
doaj   +1 more source